Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/
View Top Employees from AgendiaWebsite | http://www.agendia.com |
Revenue | $50 million |
Funding | $179.9 million |
Employees | 222 (222 on RocketReach) |
Founded | 2003 |
Address | 22 Morgan, Irvine, California 92618, US |
Phone | (949) 540-6300 |
Technologies |
JavaScript,
HTML,
PHP
+55 more
(view full list)
|
Industry | Organizations, Education, Biotechnology Research, Molecular Diagnostics in field of cancer, Colon Cancer, Breast Cancer, Personalized Medicine, Genomic Profiling, MammaPrint |
Keywords | Breast Care |
Competitors | Castle Biosciences, Inc., DxTerity, Epic Sciences, Great Basin Scientific, Inc., mdxhealth |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 6215 Companies, NAICS Code 62 Companies, NAICS Code 62151 Companies, NAICS Code 541712 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 621 Companies, NAICS Code 54171 Companies |
Looking for a particular Agendia employee's phone or email?
The Agendia annual revenue was $50 million in 2024.
Mark Straley is the CEO of Agendia.
222 people are employed at Agendia.
Agendia is based in Irvine, California.
The NAICS codes for Agendia are [6215, 62, 62151, 541712, 5417, 54, 541, 621, 54171].
The SIC codes for Agendia are [873, 87].